Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020 ; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc.... Read More

Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings

NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that expanded data from the interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD), will be presented in a late-breaking oral... Read More
Displaying 21 - 22 of 22